Phase 3 Study Results Showing 73 Percent Reduction versus Ofatumumab Alone in Risk of Disease Progression or Death to be Presented at American Society of Clinical Oncology Annual Meeting -- CHICAGO-- -- Gilead Sciences, Inc. today announced results from the Phase 3 clinical Study 119 of an investigational use of ZydeligA in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukemia . In Study 119, there was a 73 percent reduction in the risk of disease progression or death in patients receiving Zydelig in combination with ofatumumab compared to ofatumumab alone = 0.27; 95 percent CI: 0.19, 0.39; p<0.0001).